Education
About Us
Working with TipRanks
Follow Us
Evogene (EVGN)
NASDAQ:EVGN
EVGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $3.63
Previous CloseN/A
Volume47.40K
Average Volume (3M)81.88K
Market Cap
$11.42M
Enterprise Value$17.28M
Total Cash (Recent Filing)$15.31M
Total Debt (Recent Filing)$12.87M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 12, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding8,714,230
10 Day Avg. Volume63,572
30 Day Avg. Volume81,880
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$3.50Price Target Upside167.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cost ManagementCost controls have appropriately been implemented, leading to a lower than expected operating expense and an EBITDA beat despite lower revenues.
Potential GrowthCasterra is believed to be a potential catalyst for the stock via commercial successes, with material value also seen in AgPlenus and Lavie Bio.
Bears Say
Order DelaysDelays in current order delivery and a follow-on order continue to be a material headwind for investors.
Order VisibilityThere is little visibility of a follow-on order at Casterra, which was expected to be a significant commercial catalyst.
Stock DilutionThe diluted share base effectively doubled due to a $5.5M raise, contributing to the decision to lower the price target.
Evogene News
EVGN FAQ
What was Evogene’s price range in the past 12 months?
Evogene lowest stock price was $0.95 and its highest was $3.63 in the past 12 months.
What is Evogene’s market cap?
Evogene’s market cap is $11.42M.
When is Evogene’s upcoming earnings report date?
Evogene’s upcoming earnings report date is Nov 12, 2025 which is in 76 days.
How were Evogene’s earnings last quarter?
Evogene released its earnings results on Aug 19, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.63 by $0.13.
Is Evogene overvalued?
According to Wall Street analysts Evogene’s price is currently Undervalued.
Does Evogene pay dividends?
Evogene does not currently pay dividends.
What is Evogene’s EPS estimate?
Evogene’s EPS estimate is -0.43.
How many shares outstanding does Evogene have?
Evogene has 8,714,230 shares outstanding.
What happened to Evogene’s price movement after its last earnings report?
Evogene reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.63. Following the earnings report the stock price went down -4.511%.
Which hedge fund is a major shareholder of Evogene?
Currently, no hedge funds are holding shares in EVGN
Company Description
Evogene
Evogene Ltd. (NASDAQ: EVGN) is a biotechnology company focused on the development of innovative products for the agriculture, food, and pharmaceutical industries. Utilizing its proprietary computational biology platform, the company aims to improve crop yield and resilience through the discovery of new genes and traits. Evogene's core products include seed traits for crops, bio-stimulants, and agricultural chemicals designed to enhance plant growth and protection against pests and diseases.
EVGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture, with significant revenue growth and successful strategic initiatives such as partnerships and cost reductions. However, the company still faces financial challenges with operating and net losses, though these have decreased compared to the previous year.View all EVGN earnings summariesEVGN Stock 12 Month Forecast
Average Price Target
$3.50
▲(167.18% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.61% Other Institutional Investors
98.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---